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ABSTRACT
CD45 encodes a trans-membrane protein-tyrosine
phosphatase expressed in diverse cells of the
immune system. By combinatorial use of three
variable exons 4–6, isoforms are generated that
differ in their extracellular domain, thereby modulat-
ing phosphatase activity and immune response.
Alternative splicing of these CD45 exons involves
two heterogeneous ribonucleoproteins, hnRNP
L and its cell-type specific paralog hnRNP L-like
(LL). To address the complex combinatorial
splicing of exons 4–6, we investigated hnRNP L/LL
protein expression in human B-cells in relation
to CD45 splicing patterns, applying RNA-Seq. In
addition, mutational and RNA-binding analyses
were carried out in HeLa cells. We conclude that
hnRNP LL functions as the major CD45 splicing
repressor, with two CA elements in exon 6 as its
primary target. In exon 4, one element is targeted
by both hnRNP L and LL. In contrast, exon 5 was
never repressed on its own and only co-regulated
with exons 4 and 6. Stable L/LL interaction
requires CD45 RNA, specifically exons 4 and 6. We
propose a novel model of combinatorial alternative
splicing: HnRNP L and LL cooperate on the CD45
pre-mRNA, bridging exons 4 and 6 and looping
out exon 5, thereby achieving full repression of the
three variable exons.
INTRODUCTION
Many basic principles of the mammalian splicing
machinery are established by now, in particular, how the
correct splice sites in the pre-mRNA are recognized (1,2).
As we have recently learned from genomewide studies,
alternative use of splice sites and its tissue- and develop-
mental control is very common in higher eukaryotes (3,4).
Alternative splicing regulation provides not only an im-
portant level of gene regulation and enormously increases
the coding capacity of our genome, but a global and
mechanistic understanding of this process also reveals
insight into how mutations can cause human disease (5).
We know only for a few model cases in detail how the
spliceosome structure and function is modulated during
regulated alternative splicing. A relatively small set of
alternative splicing factors, both of the activator and
repressor type, interacts with the general splicing machin-
ery, at various stages of splice-site recognition and
spliceosome dynamics, and thereby determines the alter-
native splicing patterns of a very large set of target genes.
Target speciﬁcity is mediated through cis-acting elements
of the silencer or enhancer type in the pre-mRNA. Often
several splicing regulators cooperate by binding to com-
posite elements consisting of both silencers and enhancers,
resulting in a combinatorial network, the so-called splicing
code (6).
The CD45 gene represents one of the ﬁrst mammalian
genes where regulated alternative splicing has been
described (7). CD45 encodes a trans-membrane protein-
tyrosine phosphatase expressed in all nucleated hemato-
poietic cells, studied in particular in T-lymphocytes. As a
result of the combinatorial use of three variable exons 4–6,
ﬁve different isoforms are generated (8–10), and the
extracellular glycosylated domain is expressed to different
extents. Thereby, the CD45 dimerization potential and
phosphatase activity are regulated, modulating the thresh-
old of T-cell activation and the immune response (11).
Speciﬁcally, resting T-cells switch from the predominant
‘full-inclusion’ form, R456, carrying all three variable
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and R5), to the R0 form, in which all three exons 4–6 are
skipped.
For B-cells, the functional role of CD45 is less well
studied, nevertheless, it is known that CD45 alternative
exon skipping similarly contributes to the cessation of
the primary immune response (12). Upon activation,
B-cells switch to the expression of shorter CD45
isoforms (13,14), consistent with the expression of the
R0 form in terminally differentiated plasma cells.
What cis-acting elements and which factors regulate the
use of individual variable exons 4–6 has been studied in
detail by Lynch and coworkers, using a human T-cell line,
JSL1, which can be activated in vitro (15). In combination
with mutational analyses of minigenes carrying single
variable exons, several activation-responsive sequence
(ARS) elements, splicing silencers and enhancers were
mapped, and hnRNP L (called L in the following) was
characterized as a repressor, binding to CA-rich silencer
elements in exons 4–6 (16,17). In addition, based on
independent screening approaches (18–20), hnRNP
L-like (called LL in the following) was identiﬁed as
an activation-induced repressor of CD45 alternative
splicing, which in vitro binds to the exon 4 ARS element,
but not to exon 5 (18,21). However, how the L/LL
proteins cooperate to determine combinatorial alternative
splicing of CD45 has not been analyzed. Very recent work
has added another layer to the complex CD45 splicing
regulation, co-transcriptional recruitment of CTCF to
exon 5 genomic DNA, resulting in RNA polymerase II
pausing and increased exon 5 inclusion (22).
L is a multifunctional RNA-binding protein with roles
in RNA stability, IRES-mediated translation, intron-less
mRNA export [see (23) for references], riboswitch
activity in the VEGFA mRNA (24), differential
polyadenylation and alternative splicing, including L
autoregulation (16,23,25). In contrast, the paralog LL,
which shares with L 68% amino acid sequence
homology and the same domain organization of four
RNA-recognition motifs (RRMs; see 25), appears to be
specialized to splicing-regulatory roles in lymphocytes
(18–20; this study). Based on these studies there is
clearly a consensus on hnRNP LL acting as a major re-
pressor of the CD45 variable exons, and genomewide
analyses reported additional hnRNP LL targets.
However, since extensive validation and further biochem-
ical analyses of these targets have not been performed yet,
a role of hnRNP LL as a master regulator of
immune-relevant genes in T-cells (19) remains to be
conﬁrmed.
We had initially established the RNA-binding speciﬁcity
of L by in vitro SELEX (26), which revealed as high-
afﬁnity binding sites CA-repeat sequences, but also
certain CA-rich motifs (CACA and ACAC as high-score,
and TACA and CACC as low-score motifs). In natural
binding sites often closely spaced clusters of such short
motifs occur, most likely reﬂecting multiple RNA inter-
actions of a single L molecule, mediated through its four
RRMs (for examples, see 23,26). The RNA-binding
speciﬁcity of LL is similar to that of L, but distinct
(18,23), and the molecular basis for this is still unknown.
Regarding alternative splicing regulation by L versus
LL, we had identiﬁed several L targets, based on a
genomewide CA-motif search combined with alternative
splicing evidence (26). More recently, we used a combined
strategy of splice-sensitive microarray analysis and RNAi
knockdown (25) to identify more alternative splicing
targets of L; surprisingly, no LL targets were found in
HeLa cells. We noted in the same study that in HeLa
cells, L is  10-fold more abundant than LL. In sum,
these studies conﬁrmed the global role of L as an alterna-
tive splicing regulator, and are consistent with the LL
paralog acting in a cell-type-speciﬁc manner.
Here, we focus on alternative splicing of the three
variable exons in CD45, using it as a paradigm for the
complex type of combinatorial exons. In comparison to
other modes of alternative splicing (single-exon skipping;
alternative 50 and 30 splice sites), we do not yet understand
well what determines the variable use and combinations of
several adjacent alternatively spliced exons. Both paralo-
gous L/LL proteins target the three-exon unit in
CD45, and we address the general question of how two
RNA-binding proteins cooperate in generating a complex
alternative splicing pattern. We establish here and
mutationally analyze a new CD45 minigene system that
contains all three regulated exons 4–6. In addition, we
identify and make use of B-cell lines, whose LL expression
dramatically differs, to characterize the L/LL-mediated
splicing regulation of CD45.
In sum, we conclude: First, the three-exon unit can be
skipped only in the presence of LL. Second, exons 4 and
6 provide the major targets of L and LL, with LL prefer-
entially binding to two silencer elements in exon 6, but
also to a silencer element in exon 4; in contrast, exon 5
can only be corepressed in combination with exons 4 and
6. Third, L and LL interact with each other, depending on
CD45 RNA and variable exons 4 and 6, but not on exon 5.
Taken together, our data strongly argue for a model,
whereby exons 4 and 6 are repressed by L and LL inter-
acting with each other on the CD45 RNA, and exon 5 is
corepressed by looping out, resulting in full skipping of
the three-exon unit.
MATERIALS AND METHODS
Human B-cell lines and RNA-Seq analysis
Human B-cell lines Nalm-6 (DSMZ ACC128), Ramos
(DSMZ ACC603), BJAB (ATCC HB-136), ARH-77
(DSMZ ACC512), HS-Sultan (ATCC CRL1484), Raji
DSMZ ACC319), IM-9 (DMSZ ACC117), Amo-1
(DSMZ ACC538), NCI-H929 (DSMZ ACC 163), JK6L
(27), OPM-2 (DSMZ ACC50), RPMI-8226 (DSMZ
ACC402), U-266 (DSMZ ACC9), XG-1 (28) and DG75
(DSMZ ACC83) were grown in RPMI medium
(Invitrogen), or LP-1 (DSMZ ACC41) cells in IMDM
medium (Invitrogen). Both media were supplemented
with 10% FBS, 2mM L-glutamine, 1mM sodium
pyruvate, 100U/ml penicillin/streptomycin and 50mM
b-mercaptoethanol. The growth medium for XG-1 add-
itionally contained 2ng/ml IL-6. For western-blot
analysis cells were harvested and lysed with RIPA buffer
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deoxycholate, 0.1% SDS). For LL overexpression,
2 10
6 DG75 cells were transfected with 0.05, 0.2, 0.5,
or 2mg LL-V5-His plasmid (for RNA-Seq, 2mg) or, as
a control, 1mg eGFP (also for RNA-Seq), using the
Nucleofector
TM kit V (Amaxa
TM) and program T15.
After 24h cells were harvested, and RNA was isolated,
using Trizol (Invitrogen) and the RNeasy kit (Qiagen),
followed by RQ1 DNase digestion. Total RNA was
analyzed by RT-PCR or Solexa RNA-Seq; for details on
the data analysis, see Ro ¨ sel et al. (29). RNA-Seq sequence
read data have been uploaded to the GEO database
at NCBI (GSE 33013).
Constructs and DNA oligonucleotides
Expression constructs. To generate hnRNP L- and
hnRNP LL expression constructs with N-terminal
FLAG tags (FLAG-L; FLAG-LL), hnRNP L full-length
cDNA was released from the plasmid pFASTBAC
HTb-hnRNP L (30) by cutting with HindIII and XhoI.
For FLAG-LL, the hnRNP LL reading frame was cut out
by EcoRI and SalI from the pGEX-hnRNP LL construct
(25). Vector pcDNA3.1 was digested with HindIII and
XhoI, and the FLAG-tag fragment was generated by
annealing oligonucleotides with HindIII and EcoRI
ends, followed by triple ligation.
For the hnRNP LL expression construct with a
C-terminal V5-His tag, the hnRNP LL open reading
frame was cloned into TOPO vector pcDNA3.1/
V5-His-TOPO (Invitrogen), resulting in pcDNA3.1/
hnRNP LL-V5-His.
CD45 wild-type. To generate the CD45 wild-type (CD45
WT) minigene, an intermediate, containing three different
parts was cloned into pcDNA3.1, using HindIII and
ApaI: ﬁrst, 23bp of exon 2 joined with exon 3, together
with 130bp of downstream intron 3 sequence; second, the
variable exon 4 and ﬂanking intronic sequences (upstream
80bp and downstream 20bp); third, the constitutive
exon 7 with 130bp of upstream intron 6, and 20bp of
downstream intron 7. For further cloning steps an XhoI
site was inserted in intron 3, 80-bp upstream of the exon
43 0 splice site, and an EcoRI site in intron 4, 20-bp down-
stream of the exon 4 50 splice site. Subsequently exon 4 was
replaced by an insert containing all three variable exons
and shortened intervening introns (for each exon: 80-bp
upstream and 20-bp downstream sequence), produced by
three-step PCR, using the previously inserted XhoI and
EcoRI sites.
Single-exon replacement by heterologous sequences. Inserts
replacing the exonic sequence of exons 4, 5 or 6 by DUP
exon 2 sequence (31) of the same length were generated by
PCR, without altering the splice sites (ﬁrst and last 3nt of
each exon were left unchanged). For each construct,
individual restriction sites were used for cloning into the
CD45 WT construct: for the DUP-ex4 insert, XhoI and
EcoRI; for the DUP-ex5 mutant, XhoI and a PPuMI site
in intron 5; for the DUP-ex6 mutant, PpuMI and EcoRI.
Mutational analysis of potential silencer elements in exons 4
and 6. All mutants were constructed using site-directed
mutagenesis PCR. The mutant in the silencer element of
exon 4 (4/50CA) was cloned into the CD45 WT construct
using XhoI and EcoRI. Initially, exon 6 mutants were
created by PCR, using CD45 WT as a template (6/50CA,
6/mCA, 6/30CA). The double mutation in exon 6
(6/m+30CA) was introduced by two-step PCR, using the
single mutants (6/mCA, 6/30CA) as template. For the
combined mutant of exons 4 and 6 (4/50CA+6/
m+30CA) the insert, containing the exon 6 mutations,
was cut out from 6/m+30CA and inserted into the 4/
50CA construct, using PpuMI and EcoRI.
For sequences of DNA oligonucleotides, see Supple-
mentary Data.
CD45 mutational analysis and knockdown/overexpression
of L/LL proteins in HeLa cells; RT-PCR assays of
alternative splicing
siRNA-mediated knockdown in HeLa cells was performed
as previously described (25). Three days after siRNA
transfection, 6mg of CD45 WT plasmid was transfected,
using FuGENE HD transfection reagent (Roche), accord-
ing to the manufacturer’s protocol. After 24h, RNA
was isolated, as described earlier. Total RNA (1mg) was
reverse transcribed by the qScript
TM Flex cDNA kit
(Quanta), using the minigene-speciﬁc primer BGHrev.
PCR was performed with different CD45-speciﬁc primer
combinations. The knockdown efﬁciency was determined
by western blotting.
For transfections of CD45 minigenes, HeLa cells
were seeded onto 6-well plates (1.5 10
5 cells per well),
1 day before transfection. Transfections were performed
with CD45 minigene variants (4mg), using TurboFect
in vitro transfection reagent (Fermentas), according to
the manufacturer’s instructions. After 24h, RNA was
isolated, as described earlier. Total RNA (0.5mg) was
reverse-transcribed by the qScript
TM cDNA synthesis kit
(Quanta). All PCR-products obtained for CD45 primers
to exons 3 and 7 were further conﬁrmed by TOPO-cloning
(Invitrogen) and Sequencing (SeqLab).
For (co-)transfections of L, LL and CD45 minigenes,
HeLa cells were seeded onto 6-cm culture dishes (5 10
5
cells per dish), 1 day before transfection. Co-transfections,
using FLAG-L (1mg), FLAG-LL (2mg), or eGFP vector
(1mg), with CD45 minigene variants (4mg), were per-
formed, using TurboFect in vitro transfection reagent
(Fermentas), according to the manufacturer’s instructions.
After 24h, RNA was isolated and analyzed as described
earlier.
In vitro RNA-binding of hnRNP L proteins: biotin-RNA
pulldown assays
Template DNAs for in vitro transcription (AmpliScribe
TM
T7-Flash
TM transcription kit, Epicentre Biotechnologies)
of CD45 exons 4, 4/50CA, 5, 6, 6/50CA, 6/mCA, 6/30CA,
6/m+30CA, 6/DUP, 4-5-6 and 4*-5-6* were PCR-
ampliﬁed from the respective CD45 constructs, thereby
introducing the T7 promotor (Figure 5A and B, lanes
1–14). Due to PCR problems, the DUP-substituted
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were generated from EcoRI-linearized constructs. The
resulting transcripts additionally contain upstream exons
2 and 3, a shortened intron 3 and downstream the ﬁrst
20nt of intron 6.
Puriﬁed RNAs were chemically 30-biotinylated (32),
and 40pmol of each were bound to 20ml of blocked
NeutrAvidin agarose beads (Thermo Scientiﬁc), by incu-
bation overnight at 4 C in a total volume of 200ml
WB300 (20mM HEPES pH 7.5, 1mM DTT, 10mM
MgCl2, 300mM KCl, 0.01% NP-40). Bound biotinylated
RNAs were thenincubated for 30minat roomtemperature
with 30ml of HeLa nuclear extract (CILBIOTECH, Mons,
Belgium) in a ﬁnal volume of 100ml WB100 (as WB300,
with 100mM KCl). After precipitation and three wash
steps (100–300mM KCl, as indicated), bound protein
was released with 2  SDS loading buffer and incubation
at 95 C for 5min, followed by western-blot analysis.
L-LL interaction in HeLa and DG75 B-cells: FLAG
pulldown and western blot
LL overexpression in HeLa cells for FLAG immunopre-
cipitation was adjusted to 10-cm culture dishes [FLAG-LL
(3.3mg) with or without CD45 minigene variants (each
6mg)]. After 24h, cells were harvested and lysed with
RIPA buffer (see above). In a control lysate, RNA was
digested with RNase A (ﬁnal concentration 0.2mg/ml) at
room temperature for 20min. The lysates were incubated
with 20ml packed anti-FLAG M2 afﬁnity gel (Sigma)
overnight at 4 C. Beads were washed four times with
1ml TBS-T (50mM Tris pH 8.0, 150mM NaCl, 0.05%
Tween), proteins were eluted with 2  SDS-loading buffer
and analyzed by western blotting.
For western-blot analysis, cells were resuspended (or
lysed in RIPA buffer, as described) in 2  SDS loading
buffer, separated on a 10% SDS polyacrylamide gel and
transferred to a Hybond ECL nitrocellulose membrane
(GE Healthcare). Anti-L (4D11, Sigma), afﬁnity-puriﬁed
anti-LL (25), anti-FLAG (Sigma), anti-g-tubulin (GT88;
Sigma) and anti-GAPDH (Sigma) were used as primary
antibodies, HRP-conjugated anti-mouse or anti-rabbit
IgG (Sigma) as secondary antibodies. The blots were
developed using the lumi-light western-blotting substrate
(Roche).
For FLAG immunoprecipitation from DG75 B-cells,
cells were transiently transfected with 0.5mg of FLAG-
LL, or, as a control 0.5mg eGFP (Amaxa
TM), as previ-
ously described. After 24h, cells were harvested and lysed
with TBS buffer, containing 1% Triton X. Immuno-
precipitation was performed as described for HeLa cell
lysates, followed by western-blot analysis, using anti-
hnRNP L; -hnRNP LL, and, as a control, anti-GAPDH
antibodies (see above).
RESULTS
Differential hnRNP LL expression in human B-cell lines:
hnRNP LL as major repressor of CD45 exons 4–6
To address the role of the splicing repressor hnRNP LL
in CD45 alternative splicing during B-cell development,
we analyzed LL protein levels in several human B-cell
lines (Figure 1A). Western-blot analysis showed high
expression of LL in all myeloma cell lines, which represent
terminally differentiated plasma cells (right panel). In
contrast, in most cell lines derived from earlier stages,
LL expression was low or undetectable (left panel). The
pre B-cell line Nalm-6 and lymphoblastoid cell lines
ARH-77 and IM-9 that are activated and EBV-
transformed, displayed no or only very low expression
of LL. The mixed pattern of LL expression in Burkitt
lymphoma B-cell lines Ramos, BJAB, HS-Sultan and
Raji might be a result of their heterogeneous activation
and transformation status. Unlike LL, hnRNP L expres-
sion was not developmentally regulated, and most cell
lines tested expressed similar levels.
Next we compared the CD45 splicing pattern of two cell
lines that express similar levels of L, but differ in LL
expression: the Burkitt lymphoma B-cell line DG75,
which does not express detectable levels of LL, and
the myeloma cell line U-266 with high levels of LL
(Figure 1B). Consistent with LL’s role as a splicing repres-
sor, in DG75 cells the variable exons were mainly included
(R56 and R456 forms), while U-266 cells predominantly
produced the R0 form, reﬂecting skipping of exons 4–6.
In addition, overexpression of LL in DG75 cells was
sufﬁcient to switch CD45 splicing to the R0 form in a
dose-dependent manner (Figure 1C).
To further analyze the complex combinatorial splicing
pattern of the three variable CD45 exons, we used
RNA-Seq data, based on a total of 53.5 million
Illumina-Solexa 76-bp single-end reads (24.5 million
for GFP control, 29 million for LL overexpression).
Figure 2 summarizes the results, comparing DG75 cells
after GFP-control transfection (in blue) versus LL
overexpression (in red; for western-blot analysis,
compare Figure 1C, lanes 1 and 5). For the CD45
genomic region between exons 3 and 7, the read densities
(top), the ratio of read densities after LL and GFP
overexpression, as well as junction read counts (bottom)
are given. As expected, the read densities of exons 4–6
were reduced after LL overexpression. However,
comparing the various exon junctions was more inform-
ative: Most striking were the junction read counts that
represent complete skipping of exons 4–6 (R0 form):
One over 41 reads indicates that this form changed most
dramatically after LL overexpression. Similarly, skipping
of exon 6 (i.e. exons 5 and 7 junction reads) increased from
one to nine counts, indicating LL’s role as major exon 6
repressor; less dramatic, but signiﬁcant, was the repressor
effect of LL for other exon junctions.
CD45 exon-speciﬁc repression by L and LL
To analyze in detail the combinatorial regulation of the
three variable exons, we constructed a CD45 minigene
carrying exons 4–6 in between the ﬂanking constitutive
exons 3 and 7, with the intron sequences shortened to
 100nt (Figure 3, schematic below panel B). CD45
minigenes were transfected in HeLa cells, which contain
both L/LL proteins, allowing knockdown studies of either
Nucleic Acids Research, 2012,Vol.40, No. 12 5669protein, and which do not express endogenous CD45,
allowing mutational analysis.
First, L and LL were individually and in combination
downregulated by RNAi (see Figure 3A for western-blot
analysis). Second, the CD45 minigene was transfected,
followed by RT-PCR analysis, using these primer combin-
ations (Figure 3B): exons 3–7, to detect all possible
variable-exon combinations; exons 5–7, 3–5 and 4–6, for
detection of speciﬁc use of exons 6, 4 and 5, respectively.
In the control knockdown, we detected four major
RT-PCR products, reﬂecting the R456, R45, R5 and R0
forms (lane 2). L downregulation led to a signiﬁcant shift
towards the inclusion products, R45 and R456 (lane 3).
However, after downregulation of LL and of both L/LL,
the full-inclusion form R456 was almost exclusively
formed (lanes 4 and 5). The low level of remaining R0
form may be due to the minigene context and its shortened
introns, which brings the ﬂanking exons into closer prox-
imity. In sum, we conclude that LL acts as a much stronger
repressor of all three variable CD45 exons than L.
We also analyzed each of the three variable exons sep-
arately (lanes 6–17). Thereby we detected only a subset of
splice forms carrying the two respective ﬂanking exons.
Exon 6 did not respond signiﬁcantly to L knockdown,
but the LL and the double knockdown resulted in
almost complete exon 6 inclusion (lanes 6–9). In
contrast, exon 4 inclusion weakly increased upon L, and
strongly upon LL and double knockdowns (lanes 10–13).
Finally, exon 5 was never individually repressed (lanes
14–17). We conclude that both hnRNP L proteins act as
repressors, but their functional contributions clearly
differ: L acts only on exon 4; LL strongly represses both
exons 4 and 6.
Mutational analysis of CD45 exons 4 and 6: cooperation
between multiple silencer elements
We next used our CD45 minigene to study the role of
putative L/LL binding sites of exons 4 and 6, the major
targets of regulation, in determining the complex
Figure 1. HnRNP LL is differentially expressed in B-cell lines and regulates CD45 alternative splicing. (A) High LL expression correlates with the
plasma cell stage of B-cell development, while L is expressed at similar levels in most of the B-cell lines tested (names of cell lines above the lanes).
Lysates from B-cell lines derived from early, mature or activated stages of B-cell development [left panel: pre B-cell stage (pre), lymphoblastoid cell
lines (LCL) and Burkitt lymphoma B-cell lines (BL), as indicated below] and from plasma cell-derived B-cell lines (right panel: myeloma cell lines)
were analyzed by western blot for L/LL (GAPDH as a loading control). (B) CD45 alternative exon repression correlates with LL expression levels.
CD45 alternative splicing analysis by RT-PCR, comparing two different B-cell lines (Burkitt lymphoma line DG75, myeloma cell line U-266). Primer
pairs (CD45 ex3–9, 3–5 and 5–7) and products (CD45 splice forms R456, R56, R5, R0; exons 4 and 6 inclusion/skipping forms; constitutive ex8–9
product) are labeled on the side. M, DNA size markers. Below, the expression of LL, L and g-tubulin were detected by western blotting. (C) HnRNP
LL overexpression is sufﬁcient for CD45 exons 4–6 skipping and the generation of the R0 form. DG75 cells were transfected with increasing amounts
of LL-V5-His plasmid (0.05, 0.2, 0.5 or 2mg), or as a control, GFP (1mg). Total RNA was analyzed by RT-PCR (top) for CD45 alternative splicing
[products and primer pairs indicated on the right, as in panel (B)]. M, DNA size markers. Below, LL overexpression was assessed by western
blotting, with GAPDH as a control.
5670 Nucleic Acids Research, 2012,Vol.40, No. 12Figure 3. CD45 alternative splicing of a minigene in HeLa cells: speciﬁc repression of CD45 alternative exons 4–6 by hnRNP L and LL. (A)L( L),
LL (LL), or both of them (L+LL) were RNAi-downregulated in HeLa cells, including a control luciferase knockdown (luc), as conﬁrmed by
western blot for L, LL and GAPDH. (B) Following knockdown, the CD45 WT minigene was transfected, and CD45 alternative splicing was assayed
by RT-PCR (primer pairs indicated above the lanes, and schematically shown below). The RT-PCR products indicative of the R456, R45, R5 and
R0 forms (for primer pair 3–7), or for the inclusion/skipping-products (for primer pairs 5–7, 3–5 and 4–6; see brackets) are marked on the left.
All lanes come from a single gel, but were rearranged for clarity. M, DNA size markers. Below, the repressor activities of L versus LL for CD45
exons 4–6, as well as for the entire exons 4–6 unit are summarized (+ + strong; + weak;   not signiﬁcant).
Figure 2. RNA-Seq analysis of CD45 alternative splicing in DG75 B-cells. LL (or as a control, GFP) was overexpressed in DG75 B-cells, followed
by RNA-Seq analysis of total RNA. On the top, the read densities across the CD45 exons 3–7 region are represented, comparing GFP control
(in blue) and LL overexpression (in red). The numbers below indicate the respective read densities of exons 3–7. In the middle, the ratios of LL/GFP
exon read densities, normalized to the constitutive exons 3 and 7, are given, below, the exon–intron structure. The bottom part summarizes the
absolute junction read counts, with the arrows indicating changes in a particular splice event after LL overexpression (" increase; # decrease).
Nucleic Acids Research, 2012,Vol.40, No. 12 5671alternative splicing pattern (Figure 4; see panel B for a
schematic of minigenes, mutations introduced and
splicing phenotypes).
As seen earlier, splicing of CD45 WT resulted in a
mixture of R456, R45, R5 and R0 forms (lane 2).
Mutation of the single CA cluster of L/LL binding sites
in exon 4 (4/50CA) resulted in several striking changes:
The R45 form strongly increased; the R5 form dis-
appeared, and instead, a new splice form with only exon
4 included appeared (R4); in addition, the R0 form
decreased (lanes 2 and 3). The new R4 from indicates
that the 50CA mutation in exon 4 inactivated a silencer
element. The concomitant strong increase in the R45 form
argues for efﬁcient corepression of exons 4 and 5.
Moreover, LL overexpression with the 4/50CA mutant
minigene completely shifted the splicing pattern to the
R4 and R0 forms, different from CD45 WT, where only
the R0 form was observed (compare insets below lanes 2
and 3). In contrast, overexpression of L had no effect,
probably due to the high levels of endogenous L.
Next, a series of three exon 6 mutations were assayed,
designed to selectively inactivate the 50 terminal, the
middle and the 30 terminal CA cluster. Compared with
alternative splicing of CD45 WT, the 6/50CA mutation
Figure 4. Mutational analysis of CD45 silencer elements in exons 4 and 6. (A) CD45 WT minigenes and mutant derivatives [as indicated above the
lanes; see panel (B) for schematic representations] were transfected in HeLa cells, followed by RT-PCR with primers against CD45 exons 3 and 7
(products represented on the right). For CD45 WT and mutants 4/50CA, 6/m+30CA and 4/50CA+6/m+30CA, additional cotransfections were done
with GFP (as control), with FLAG-L or FLAG-LL (as indicated above the lanes), followed by RT-PCR assays with exons 3–7 or 4–6 primer pairs
(as indicated). The asterisk marks an unspeciﬁc PCR product, which could not be identiﬁed. M, DNA size markers. (B) Summary of CD45 mutant
minigenes used (the position of mutations marked by thick vertical lines). The mutated nucleotide positions in exons 4 and 6 are speciﬁed below, in
each case with the CA elements in bold letters and the mutations underlined. Spliced CD45 isoforms are represented on the right side, with single
and double arrows indicating changes compared to wild-type.
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the 50CA cluster does not play an important role in exon
6 repression (lane 4).
Mutating the middle CA element in exon 6 (6/mCA;
lane 5), however, did change the splicing pattern: Both
the R45 and R5 forms decreased, and a new combination
of exons 5 and 6 appeared, the R56 form. This suggests
that the mCA mutation inactivated a silencer element in
exon 6, resulting in more exon 6 inclusion, which appears
to be coupled with exon 5, explaining the new R56 form.
Inactivating the 30 terminal CA cluster in exon 6
(6/30CA; lane 6) further enhanced all effects observed for
the mutated middle element: increased R56 form,
decreased R5 form and undetectable R45 form. This
indicates that the 30 terminal CA cluster functions as a
more potent silencer than the middle CA cluster does.
Combining the mutations of both middle and 30
terminal silencers in exon 6 (6/m+30CA; lane 7 and
insert below) further enhanced the effects seen with both
separate mutations. This strongly argues for two function-
ally independent silencers. Interestingly, after LL
overexpression, exon 6 by itself could be detected (R6
form), further supporting the silencer role of both CA
clusters.
The combination of mutations in exons 4 and 6
described earlier (4/50CA+6/m+30CA; lane 8 and insert
below) showed the most dramatic splicing phenotype: The
full-inclusion form R456 was strongly increased, reﬂecting
the combined inactivation of all three silencers in exons 4
and 6; in addition, we detected no partial-inclusion
forms anymore (R56 and R5). Instead, the R4 form
appeared, and this unusual form strongly increased upon
LL overexpression, consistent with what we previously
found for the 4/50CA mutant (compare lanes 8 and 3,
and inserts below). Under these conditions, another
unusual, minor spliced form was detected, R46, with
exons 4 and 6 included, but not exon 5; only in this
case, when silencers in both exons 4 and 6 were
mutated, we have seen this exceptional joining of exons
4 and 6.
Stable complex formation of L and LL on CD45 exons 4
and 6: mutational analysis in vitro
In order to correlate these splicing changes of CD45
mutant minigenes with L/LL binding, we next assayed
the in vitro interaction with WT and mutant single-exon
4–6 RNAs (Figure 5A). RNAs were 30-biotinylated and
bound to Neutravidin agarose, followed by incubation in
HeLa nuclear extract and western-blot analysis of bound
protein. Binding efﬁciencies were generally lower for L
than for LL, which may be due to their different protein
levels in nuclear extract. Comparing the binding activities
of L versus LL, both proteins behaved similarly: Exons 4
and 6 were efﬁciently bound, whereas exon 5 as well as
the mutant exon 4 with the inactivated silencer element
(exon 4/50CA) did not signiﬁcantly bind L/LL (lanes 1–
5). L/LL association greatly differed for the four exon 6
mutant RNAs (lanes 6–10): Whereas mutation of the 50
terminal CA element had only a minor effect (exon
6/50CA), mutations of both middle (/mCA) and 30
elements (/30CA) greatly reduced L/LL binding, and
their combination (/m+30CA) abolished L/LL binding,
similarly as substitution of the entire exon 6 (/DUP).
In sum, these in vitro binding data demonstrate that
both L and LL bind to exons 4 and 6; in contrast,
binding to exon 5 is insigniﬁcant. Mutations in the three
silencer elements of exon 6 differentially affected L/LL
interaction, correlating well with their effects on alterna-
tive splicing (see Discussion).
Next we tested, whether the combination of all three
variable exons in cis inﬂuences the afﬁnities for L/LL.
Biotinylated RNAs, containing exons 4–6 together with
shortened intervening introns, were analyzed for L/LL
binding under different stringencies of washing
(Figure 5B). The LL binding efﬁciency for the exons
4-5-6 RNA (lane 4) reﬂected combined binding to the
individual exons (panel A, lane 2, and panel B, lanes 2
and 3). Increasing stringency during washing to 300mM
KCl reduced LL afﬁnity for both exon 6 and for exons
4-5-6 by  50% (panel B, compare lanes 3 and 4 and 12
and 13).
In contrast to LL, binding of L to exons 4-5-6 RNA was
increased by >20-fold, compared to individual-exon
RNAs (lanes 3 and 4). L binding to the three-exon RNA
was stable at 200mM salt, and reduced by only  50% at
300mM salt (lanes 4, 8 and 13). The dramatic increase in
L binding to the exon 4-5-6 RNA suggests the formation
of a salt-stable complex, containing both L and LL.
In addition, a mutant derivative of exon 4-5-6 RNA
(exon 4*-5-6*, containing the 4/50CA and 6/m+30CA
silencer mutations), showed strongly reduced afﬁnity
towards L/LL, and increased salt sensitivity (lanes 4/5,
8/9, 13/14). Since the silencer mutations inactivate the
major LL targets of alternative splicing regulation, this
suggests that stable L association is mediated through LL.
Finally, we also determined which exons contribute to
the assembly of this stable L/LL complex on the CD45
pre-mRNA, using—under stringent conditions—mutant
derivatives, where either of the three variable exons was
substituted by heterologous sequence (CD45/DUP-ex4,
-ex5 and -ex6; Figure 5B, lanes 15–18; for alternative
splicing of these mutant CD45 pre-mRNAs, see
Supplementary Figure S1). Whereas the exons 4 and 6
substitutions resulted in a moderate to strong reduction
of L/LL binding, the complete substitution of exon 5 even
increased the L/LL binding efﬁciency. We conclude that
for the assembly of the stable three-exon complex, exon 6
(with two silencers) is more important than exon 4 (with
one silencer), but that exon 5 sequence is not required.
CD45 exons 4–6 dependent in vivo interaction of hnRNP
L and LL
Our in vitro binding data suggest the formation of a stable
complex on the CD45 pre-mRNA containing both L and
LL. Therefore we tested whether both paralogs interact
in vivo with each other in a CD45-dependent manner,
using cotransfection of FLAG-LL and the CD45
minigene with all three variable exons in HeLa cells
(Figure 6A). HeLa cells provide an ideal model system
for this, since the CD45 minigene reproduces the normal
Nucleic Acids Research, 2012,Vol.40, No. 12 5673Figure 5. In vitro binding of hnRNP L and LL to CD45 exons 4–6. (A) RNA binding of hnRNP L/LL correlates with repressor activity. Equimolar
amounts of 30-biotinylated RNAs, containing wild-type or mutant versions of each variable exon (as indicated above the lanes and schematically on
the right), were prebound to Neutravidin agarose, followed by incubation in HeLa nuclear extract, washing at 100mM KCl, release of bound protein
and western-blot analysis for LL, L and, as a control, GAPDH. For comparison, nuclear extract input was analyzed in parallel (lanes 1; 20% for LL
and GAPDH; 5% for L). Quantitation of L/LL pulldown is given below each lane (in % relative to the input, including SDs). (B) An RNA
containing CD45 exons 4-5-6 in cis stabilizes hnRNP L binding, depending on exons 4 and 6. As described in panel (A), pre-mRNAs, containing
either the wild-type sequence (exons 4-5-6) or a mutant derivative, combining silencer mutations in exons 4 and 6 (exons 4*-5-6*), were compared
with single-exons 5 and 6 RNAs for L versus LL binding in nuclear extract (lanes 1–14). Complex stability was tested by washing under different salt
conditions (as indicated on top: 100–300mM KCl). In addition, L/LL binding to mutant exon 4-5-6 derivatives were compared, in which one of the
three exons was replaced by DUP sequence (DUP-ex4, -ex5 and -ex6; lanes 15–18).
5674 Nucleic Acids Research, 2012,Vol.40, No. 12alternative splicing pattern (see above), and there is no
endogenous CD45 expression.
HeLa cells were transfected with the FLAG-LL expres-
sion construct, either alone or in combination with the
CD45 WT minigene. Lysates were prepared, treated with
RNase or left untreated, followed by FLAG pulldown
assays (Figure 6B, lanes 1–6) and western-blot detection
of coprecipitated L (top panel), and, as controls, of trans-
fected LL and GAPDH (middle and bottom panels).
Comparing in each case input and FLAG-pulldown
(bound; lanes i and b, respectively) clearly showed that
L could be recovered only when CD45 was cotransfected
with LL (lanes 1–4). L coprecipitation depended on RNA
(lanes 4 and 6), required FLAG-LL cotransfection (lanes
7–9), and was CD45-speciﬁc (lanes 10–12). L-LL inter-
action could also be detected in DG75 cells that express
endogenous CD45 (Supplementary Figure S2). Taken
together, these data provide strong evidence for a stable,
RNA-dependent and CD45-speciﬁc L/LL interaction.
Which of the three variable CD45 exons is necessary for
the L/LL interaction (Figure 6C)? In comparison to CD45
WT (lanes 13 and 14), we tested substitutions of either of
the variable exons (DUP-ex4, -ex5 and -ex6; lanes 15–20).
When exons 4 or 6 were substituted, L coprecipitation was
consistently strongly reduced, in contrast to the exon 5
substitution. We conclude that exons 4 and 6 are particu-
larly important for the CD45-dependent L/LL interaction.
DISCUSSION
B-cells as a new model system to study cooperation of the
hnRNP L/LL paralogs in alternative splicing regulation
HnRNP L and LL are two paralogous RNA-binding
proteins, closely related in domain organization, yet with
different ranges of function and cellular distribution.
Whereas the abundant L is clearly multifunctional,
including its activity as a global splice regulator, LL
appears to operate primarily in lymphocytes, with CD45
pre-mRNA as its major target of alternative splicing
regulation. Since both paralogs often coexist in the same
cell type, this raises the question, whether and how they
cooperate in splicing regulation. The same question
applies to other known splicing regulators, that exist as
paralogs, such as PTB/nPTB/ROD1 (33), Rbfox1/2 (34),
ESRP1/2 (35), or the multiple members of the CELF
and MBNL families (36).
Here we have introduced B-cells as a new model system
to investigate the functional contributions of L versus LL
in CD45 alternative splicing regulation. In contrast to
hnRNP L, LL protein expression strongly correlated
with the terminally differentiated plasma cell state
and with repression of the exons 4–6 unit (Figure 1). We
selected one B-cell line, DG75, that does not express LL,
providing a unique opportunity to study in a biologically
relevant cell system the speciﬁc contribution of LL:
Figure 6. CD45 RNA-dependent interaction of hnRNP L and LL in vivo.( A) Schematic of CD45 minigenes and experimental protocol.
(B) Interaction depends on CD45 RNA expression: HeLa cells were transfected with either FLAG-LL alone (lanes 1 and 2), or in combination
with the CD45 WT minigene (lanes 3–6). As controls, CD45 WT was cotransfected with GFP (lanes 7–9), or FLAG-LL with GFP (lanes 10–12).
Lysates were prepared without or with RNase treatment (as indicated), followed by FLAG pulldown assays. Coprecipitated L was detected by
western blot, comparing input (lanes i; 2.5%) and bound material (lanes b; 20%), in parallel with LL, FLAG tag and loading control GAPDH.
(C) Interaction depends on exons 4 and 6: Additional FLAG pulldown assays were performed after cotransfections of FLAG-LL and CD45 WT
(lanes 13 and 14) or mutant minigenes carrying DUP-substituted exons 4–6 (DUP-ex4, -ex5, -ex6; lanes 15–20).
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splicing from exon inclusion to the full-skipping form,
consistent with CD45 isoform expression after LL
overexpression and knockdown in BL41 or BJAB B-cell
lines, respectively (19).
More insight into combinatorial CD45 splicing was
obtained by RNA-Seq analysis (Figure 2): Most striking
was the effect of LL overexpression on skipping of all
three variable exons, with exon 6 providing the major
functional target of LL. Exon 5 repression was only
detected in combination with exons 4 and 6, never by
itself, that is no junction reads joining exons 4 and 6
were detectable. This is consistent with previous analyses
of CD45 alternative splicing in T-cells (37) and suggests
that exon 5 is corepressed with its ﬂanking exons 4 and 6.
Mutational analysis of CD45 combinatorial alternative
splicing
We used a CD45 minigene construct with all three variable
exons 4–6, which allowed for the ﬁrst time mutational
analysis in their natural multi-exon context. Since the
complex, L/LL-regulated CD45 splicing pattern was
reproduced in HeLa cells (Figure 3), this implies, ﬁrst,
that the minigene carries all essential regulatory
sequence elements. Second, HeLa cells contain all neces-
sary regulatory factors, and apparently, no additional
lymphocyte-speciﬁc factors are required. The only differ-
ence between the splicing patterns of the CD45 minigene
in HeLa cells and the endogenous CD45 in B-cells is the
formation of the R45 form (HeLa cells) instead of the R56
form (B-cells). Most likely, this reﬂects the stronger
repression of exon 6 by LL present in HeLa cells versus
DG75 B-cells, where only L is present.
Individual knockdown of either L or LL in this system
allowed monitoring the repressor activity of either paralog
on each of the three variable exons (Figure 3): Clearly,
exon 6 is speciﬁcally repressed by LL, not by L, whereas
for exon 4 we detected strong repression by LL and a basal
repressive function of L. In contrast, exon 5 by itself was
not signiﬁcantly repressed by either paralog. This indicates
that exon 5 can be repressed only in combination with
exons 4 and 6, consistent with our RNA-Seq data.
We used the CD45 minigene to analyze potential
silencer elements in their natural three-exon context
(Figure 4). Silencer elements were predicted, based on
our SELEX study (26) as clusters of three to four
binding sites, separated by short spacers. In such a com-
posite binding element three or all four RRMs of hnRNP
L/LL would recognize individual adjacent motifs. We
predicted a single silencer element in exon 4, and three
in exon 6. For exon 5, no clustered binding motifs could
be identiﬁed. In addition to alternative splicing, we also
determined in vitro binding of L/LL to CD45 variable
exons 4–6, comparing the effects of these mutations
(Figure 5).
The splicing analysis of the mutated CD45 exons
strongly supported the silencer elements predicted for
exon 4 (4/50CA mutant) and for two of the exon 6
elements (6/mCA and 6/30CA mutants). Only the
element predicted in the 50 half of exon 6 (6/50CA
mutant) had no signiﬁcant effects on alternative splicing
nor binding, probably because it consists only of three
motifs of the low-score type. Moreover, in all cases the
effects on exon repression correlated very well with L/LL
binding (compare Figures 4 and 5A). Since complete sub-
stitution of exon 4 (DUP-ex4) resulted in a nearly identical
splicing pattern as the exon 4/50CA silencer mutation,
there appears to be only a single silencer in exon 4
(compare Figure 4A, lane 3, and Supplementary Figure
S1A, lane 5). We conclude that this element in exon 4 and
two silencer elements in exon 6 (mCA and 30CA) mediate
repression by L/LL.
How do these results compare with previous mutational
data, all based on minigenes with single variable exons and
studied in the T-cell system? Our predicted silencer
element in exon 4 largely overlaps with the ARS
element, which is necessary and sufﬁcient for exon 4
skipping (38); in addition, Topp et al. (18) found that
ARS mutation in exon 4 affects L/LL binding in vitro.
Regarding exon 6, both strong silencers we identiﬁed
based on predicted high-afﬁnity L/LL binding sites
(6/mCA and 6/30CA) overlap with silencer-active regions
mapped by linker-scanning mutagenesis (17).
Comparing the exon 6 mutations 6/mCA, 6/30CA and
the combination 6/mCA+30CA, we note that these
resulted in similar effects, with increasing intensity. This
strongly argues for two functionally independent silencers
in the center and 30 region of exon 6, which does not rule
out the possibility that these two silencers may also partly
synergize by increasing the local concentration of LL.
With both of them inactivated, the R45 switches com-
pletely to the R56 form, which is paralleled by complete
loss of L/LL binding to exon 6. We interpret this to reﬂect
a competition between exons 4 and 6 for L/LL-mediated
repression: In the WT situation, LL primarily targets exon
6 for repression, resulting in co-inclusion of exons 4 and 5
(R45 form); if after silencer mutation exon 6 cannot be
repressed anymore, L/LL repress exon 4 with its
lower-afﬁnity silencer element better, thereby switching
from exons 4–5 to exons 5–6 co-inclusion (R56 form).
Within exon 5 there are no predicted high-afﬁnity
binding sites for L/LL, consistent with lack of signiﬁcant
L/LL binding in vitro. Therefore we did not pursue
detailed mutational analysis in this region; however,
some conclusions can be drawn from substituting the
entire exon 5 sequence (DUP-ex5). First, and in contrast
to exons 4 and 6, substituting the exon 5 by heterologous
sequence did not change the splicing pattern in the
three-exon context, consistent with the idea that exon 5
is mainly co-regulated with its ﬂanking exons 4 and 6
(Supplementary Figure S1A, lanes 2, 5, 8 and 11).
Surprisingly, however, LL overexpression with the exon
5-substituted CD45 did not shift all splicing to the R0
type, as in the case of the WT construct (compare lanes
4 and 10); this suggests that exon 5 corepression may
require exon-speciﬁc sequences.
Model
In summary, we propose the following model to explain
combinatorial alternative splicing of the three CD45
5676 Nucleic Acids Research, 2012,Vol.40, No. 12variable exons (Figure 7). This model focuses on the
cooperation of the paralogous L/LL factors, and does
not take into account that additional factors may likely
participate (39) and that cotranscriptional splicing (22)
may add another level of regulation:
CD45 variable exons 4 and 6 are recognized by L and
LL, requiring exonic splicing silencers in exons 4 and 6
(red bars). LL efﬁciently represses both exons 4 and 6, L
preferentially exon 4. In contrast, exon 5 does not stably
bind L/LL, and therefore cannot be repressed individually
(no R46, but R45 and R56 forms). Instead, it is
corepressed with exons 4 and 6. Which of the R45 or
R56 form dominates, is determined by the presence of L
versus LL (left part): If both L and LL are present (as in
HeLa cells), exon 6 can be repressed individually, resulting
in the R45 form, or both exons 4 and 6 are repressed,
resulting in the R5 form. If only L is present (as in
DG75 B-cells), exon 4 is repressed, resulting in the
predominant R56 form. Additional supportive evidence
comes from our mutational analysis: Successive weaken-
ing of the exon 6 silencers brings about a gradual shift
from the R45 to the R56 form.
In addition to this individual exon 4 and exon 6 repres-
sion modes, our model proposes a repression mode
depending on both exons 4 and 6 (right part). High LL
levels (as in plasma cells) lead to a cross-exon 4–6 inter-
action and a stable RNP complex, in which exon 5 is
looped out. This model is supported by both in vitro
L/LL binding data and in vivo interaction assays: First,
L binds to an exon 4-5-6 pre-mRNA with much higher
efﬁciency than to the separate three exons, which can be
explained by a stabilization or additional recruitment of L
in the three-exon complex. Second, stable in vivo L-LL
interaction depends on CD45 RNA and on both exons 4
and 6, but not exon 5 sequence. As a result of the assembly
of such a stable CD45 pre-mRNA/L-LL RNP complex,
with exon 5 looped out, all three variable exons are
skipped, generating the R0 form.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online:
Supplementary Materials and Methods and Supple-
mentary Figures 1 and 2.
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